Importance of chest HRCT in the diagnostic evaluation of fibrosing interstitial lung diseases
- PMID: 34076172
- PMCID: PMC8332714
- DOI: 10.36416/1806-3756/e20200096
Importance of chest HRCT in the diagnostic evaluation of fibrosing interstitial lung diseases
Abstract
Many conditions result in chronic interstitial lung disease (ILD), being classified as fibrosing ILDs, including idiopathic pulmonary fibrosis, connective tissue diseases, sarcoidosis, and fibrotic hypersensitivity pneumonitis. HRCT plays an important role in the clinical evaluation of fibrosing ILDs. Current treatment perspectives are encouraging and reinforce the need for HRCT scans of adequate technical quality for early detection of fibrosing ILD. Despite efforts in this regard, the significance and management of imaging findings of early interstitial lung abnormalities have yet to be clarified. After identification of CT findings consistent with fibrosing ILD, radiologists must be able to identify characteristic morphological patterns and, in some cases, features of specific clinical entities. In cases in which HRCT features are not sufficiently specific for a definitive diagnosis, HRCT can aid in selecting the best site for surgical lung biopsy. CT follow-up is useful for identifying progressive fibrosing ILDs and detecting complications unrelated to the underlying disease, including infections, acute exacerbations, and neoplasms. Automated quantification tools have clinical applicability and are likely to be available for use in imaging analysis in the near future. In addition, incorporation of CT evaluation into scoring systems based on clinical and functional parameters for staging fibrosing disease is likely to become valuable in determining prognosis. Knowledge of the clinical applications of CT evaluation is essential for specialists managing patients with fibrosing ILD and can have a positive impact on the clinical course of the disease.
Inúmeras doenças determinam dano intersticial crônico no parênquima pulmonar e são agrupadas com a denominação de pneumopatias intersticiais fibrosantes, incluindo fibrose pulmonar idiopática, doenças do colágeno, sarcoidose, pneumonite por hipersensibilidade fibrótica etc. Entre os métodos complementares à avaliação clínica, a TCAR tem um papel relevante. Perspectivas atuais de tratamento são encorajadoras e reforçam a necessidade de realização de estudos com técnica adequada, visando a detecção confiável de acometimento intersticial fibrosante o mais precocemente possível. Embora esforços tenham sido direcionados nesse sentido, o significado e manejo de anormalidades pulmonares intersticiais incipientes, detectadas nos estudos de imagem, ainda não são claros. Uma vez detectado o acometimento fibrosante, é importante que o radiologista conheça aspectos característicos de determinados padrões morfológicos e reconheça elementos que possam apontar para entidades clínicas específicas. Em casos nos quais a especificidade dos achados não é suficiente para a suspeição diagnóstica, as imagens de TC servem de guia para a escolha de sítios para biópsia cirúrgica. O seguimento evolutivo é útil para a determinação de pneumopatias fibrosantes progressivas e para a detecção de complicações não relacionadas à doença de base, como infecções, exacerbação aguda e neoplasias. Ferramentas automatizadas de quantificação têm aplicabilidade clínica e devem estar acessíveis para a análise imagética no futuro próximo. Além disso, a incorporação da avaliação tomográfica a escores com parâmetros clínicos e funcionais de estadiamento do acometimento fibrosante poderá se tornar valiosa na determinação prognóstica. O conhecimento das diversas aplicabilidades clínicas do método tomográfico é fundamental aos especialistas que acompanham esses pacientes, podendo impactar positivamente sua trajetória clínica.
Figures








Comment in
-
The challenge of diagnosing interstitial lung disease by HRCT: state of the art and future perspectives.J Bras Pneumol. 2021 Jun 23;47(3):e20210199. doi: 10.36416/1806-3756/e20210199. J Bras Pneumol. 2021. PMID: 34190867 Free PMC article. No abstract available.
Similar articles
-
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.
-
The natural history of progressive fibrosing interstitial lung diseases.Respir Res. 2019 Mar 14;20(1):57. doi: 10.1186/s12931-019-1022-1. Respir Res. 2019. PMID: 30871560 Free PMC article. Review.
-
Health care costs and utilization of progressive fibrosing lung disease by underlying interstitial lung disease type.J Manag Care Spec Pharm. 2024 Feb 3;30(2):163-174. doi: 10.18553/jmcp.2024.30.2.163. J Manag Care Spec Pharm. 2024. PMID: 38308627 Free PMC article.
-
Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.Adv Ther. 2021 Jul;38(7):4100-4114. doi: 10.1007/s12325-021-01786-8. Epub 2021 Jun 17. Adv Ther. 2021. PMID: 34156606 Free PMC article.
-
Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.Mod Rheumatol. 2021 Jan;31(1):13-19. doi: 10.1080/14397595.2020.1826665. Mod Rheumatol. 2021. PMID: 32964766 Review.
Cited by
-
The radiologist's role in detecting systemic anticancer therapy-related interstitial lung disease: an educational review.Insights Imaging. 2024 Aug 1;15(1):191. doi: 10.1186/s13244-024-01771-z. Insights Imaging. 2024. PMID: 39090512 Free PMC article. Review.
-
Radiologic approach and progressive exploration of connective tissue disease-related interstitial lung disease: meeting the curiosity of rheumatologists.J Rheum Dis. 2024 Jan 1;31(1):3-14. doi: 10.4078/jrd.2023.0042. Epub 2023 Oct 18. J Rheum Dis. 2024. PMID: 38130961 Free PMC article. Review.
-
Spatial lung imaging in clinical and translational settings.Breathe (Sheff). 2024 Oct 1;20(3):230224. doi: 10.1183/20734735.0224-2023. eCollection 2024 Oct. Breathe (Sheff). 2024. PMID: 39360023 Free PMC article. Review.
-
Imaging in the diagnosis and management of fibrosing interstitial lung diseases.Breathe (Sheff). 2024 Mar;20(1):240006. doi: 10.1183/20734735.0006-2024. Epub 2024 May 14. Breathe (Sheff). 2024. PMID: 38746908 Free PMC article. Review.
-
Collagen 1a1 Expression by Airway Macrophages Increases In Fibrotic ILDs and Is Associated With FVC Decline and Increased Mortality.Front Immunol. 2021 Nov 17;12:645548. doi: 10.3389/fimmu.2021.645548. eCollection 2021. Front Immunol. 2021. PMID: 34867934 Free PMC article.
References
-
- American Thoracic SocietyEuropean Respiratory Society American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001 [published correction appears in Am J Respir Crit Care Med2002 Aug 1;166(3):426]. Am J Respir Crit Care Med. 2002;165(2):277–304. doi: 10.1164/ajrccm.165.2.ats01. - DOI - PubMed
-
- Travis TD, Costabel U, Hansell DM, King TE, Jr, Lynch DA, Nicholson AG. An official American Thoracic Society/European Respiratory Society statement Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–748. doi: 10.1164/rccm.201308-1483ST. - DOI - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical